- Home
- LPTX vs MTNB Comparison
LPTX vs MTNB Comparison
Compare LPTX & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- MTNB
- Stock Information
- Founded
- LPTX 2011
- MTNB 2013
- Country
- LPTX United States
- MTNB United States
- Employees
- LPTX N/A
- MTNB N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- MTNB Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- MTNB Health Care
- Exchange
- LPTX Nasdaq
- MTNB Nasdaq
- Market Cap
- LPTX 11.1M
- MTNB 10.8M
- IPO Year
- LPTX N/A
- MTNB N/A
- Fundamental
- Price
- LPTX $0.75
- MTNB N/A
- Analyst Decision
- LPTX Hold
- MTNB Hold
- Analyst Count
- LPTX 1
- MTNB 1
- Target Price
- LPTX N/A
- MTNB N/A
- AVG Volume (30 Days)
- LPTX 7.6M
- MTNB 56.8K
- Earning Date
- LPTX 11-12-2025
- MTNB 11-12-2025
- Dividend Yield
- LPTX N/A
- MTNB N/A
- EPS Growth
- LPTX N/A
- MTNB N/A
- EPS
- LPTX N/A
- MTNB N/A
- Revenue
- LPTX N/A
- MTNB N/A
- Revenue This Year
- LPTX N/A
- MTNB N/A
- Revenue Next Year
- LPTX N/A
- MTNB N/A
- P/E Ratio
- LPTX N/A
- MTNB N/A
- Revenue Growth
- LPTX N/A
- MTNB N/A
- 52 Week Low
- LPTX $0.22
- MTNB $0.47
- 52 Week High
- LPTX $4.79
- MTNB $4.25
- Technical
- Relative Strength Index (RSI)
- LPTX 63.63
- MTNB 52.58
- Support Level
- LPTX $0.46
- MTNB $1.83
- Resistance Level
- LPTX $0.98
- MTNB $1.97
- Average True Range (ATR)
- LPTX 0.11
- MTNB 0.13
- MACD
- LPTX 0.03
- MTNB -0.01
- Stochastic Oscillator
- LPTX 51.58
- MTNB 34.88
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.